Compare · KLTO vs TECH
KLTO vs TECH
Side-by-side comparison of Klotho Neurosciences Inc. (KLTO) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLTO and TECH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TECH carries a market cap of $8.48B.
- Over the past year, KLTO is up 187.3% and TECH is up 7.8% - KLTO leads by 179.5 points.
- TECH has hit the wire 6 times in the past 4 weeks while KLTO has been quiet.
- TECH has more recent analyst coverage (22 ratings vs 0 for KLTO).
- Company
- Klotho Neurosciences Inc.
- Bio-Techne Corp
- Price
- $0.52+0.48%
- $54.19+3.79%
- Market cap
- -
- $8.48B
- 1M return
- +113.82%
- +2.81%
- 1Y return
- +187.29%
- +7.82%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 22
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest KLTO
- Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
- Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
- Chief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)
- Director El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)
- Director Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)
- Director Hirschman Shalom was granted 350,000 shares, increasing direct ownership by 63% to 908,873 units (SEC Form 4)
- Director Mcgarity Jon was granted 350,000 shares, increasing direct ownership by 571% to 411,277 units (SEC Form 4)
Latest TECH
- Chief Executive Officer Kelderman Kim converted options into 11,344 shares and covered exercise/tax liability with 1,363 shares, increasing direct ownership by 19% to 63,058 units (SEC Form 4)
- CFO Hippel James covered exercise/tax liability with 56,097 shares and converted options into 62,000 shares, increasing direct ownership by 4% to 148,625 units (SEC Form 4)
- SEC Form 4 filed by Kelderman Kim
- Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
- Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
- SEC Form 4 filed by Bohnen Shane
- Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp
- Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
- SEC Form 4 filed by President - Diag & Spatial Bi Crouse Steven C.
- New insider Crouse Steven C. claimed ownership of 5,894 shares (SEC Form 3)